Masco Corp (MAS)

$57.69 0.14 (0.24%)

19:00 EDT MAS Stock Quote Delayed 30 Minutes

Volume:

Previous Close $57.69

Market Cap 17.91B

PE Ratio 33.94

EPS 1.7

Volume (Avg. Vol.) 3.34M

Day's Range 57.21 - 58.50

52-Week Range 27.04 - 60.16

Dividend & Yield 0.44 (0.75%)

MAS Stock Predictions, Articles, and Masco Corp News

From InvestorPlace
From the Web

Stock Market Today: Peloton to $5?; Nintendo Switch to China

By Bret Kenwell, InvestorPlace Contributor Dec 10, 2019

Netflix fell after being downgraded, despite a strong Golden Globes nominations showing. Here's what happened in the stock market today.

3 Big Stock Charts for Monday: Masco, Newmont Mining and O’Reilly Automotive

By James Brumley, InvestorPlace Feature Writer Jan 14, 2019

The stock charts of ORLY, NEM and MAS look better positioned to make trade-worthy moves this week than most other names.

3 Big Stock Charts for Thursday: Masco, Ralph Lauren and Microchip Technology

By James Brumley, InvestorPlace Feature Writer Nov 29, 2018

The stock charts of MCHP, MAS and RL deserve a closer technical look at today's trading action kicks off.

3 Big Stock Charts for Monday: WestRock, Masco and Goodyear Tire & Rubber

By James Brumley, InvestorPlace Feature Writer Jul 30, 2018

The stock charts of WRK, MAS and GT are dropping better hints of what's to come than most other charts are. Here's what you need to know.

7 Stocks That Could Take a Trade-War Hit

By Will Ashworth, InvestorPlace Contributor Jun 14, 2018

Republicans in 30 states will have to answer to constituents soon enough as to why their biggest trading partner is being unfairly targeted by the White House with tariffs that are potentially illegal and will hurt American and Canadian consumers alike.

9 ETFs to Buy if Trump Tax Reform is Enacted by Year End

By Zacks Investment Research Apr 28, 2017

Trump's tax reform plans have put these 9 ETFs in play

Compare Brokers

2 Stocks to Buy, 2 Stocks to Avoid Amid the Canadian Lumber Tariff

By Josh Enomoto, InvestorPlace Contributor Apr 26, 2017

President Trump showed everyone who's boss by imposing the Canadian lumber tariff, which will divide the markets into winners and losers.

Start Your Week Right With These 93 Stock Recommendations

By Louis Navellier, Editor, Growth Investor Jan 24, 2017

It pays to stay on top of the latest profit opportunities, and with my updated Portfolio Grader ratings you can start right here

Hottest Manufacturing Stocks Now – RELV IIN LMT ZGNX

By Portfolio Grader Oct 25, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

5 Dividend Stocks Increasing Payouts – AXP ACN YUM MAS OGE

By Brian Bollinger, Simply Safe Dividends Oct 3, 2016

Five notable dividend stocks raised their payouts last week, including YUM! Brands (YUM), and American Express (AXP).

MHK, MAS and SHW: Your Best Housing Bets in 2016

By Adam Johnson, Founder and Author, Bullseye Brief Jun 9, 2016

Not all housing data is good, but what bright spots there are point to home furnishers like Masco (MAS) and Sherwin-Williams (SHW), not homebuilders.

5 Stocks With Great Earnings Growth — SFNC OB CSGS MAS ENG

By Portfolio Grader May 17, 2016

This week, these five stocks have the best ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

Compare Brokers

4 DIY Stocks to Buy to Outbuild the Market

By Josh Enomoto, InvestorPlace Contributor May 13, 2016

As yesterday's market leaders fall by the wayside, look to the home furnishing and DIY industry to offer the best stocks to buy this year. HD, SMG, MAS and UFPI stock are some of the best picks out of the bunch.

5 Stocks With Strong Earnings Growth — CUBE TNP CSGS MAS ENG

By Portfolio Grader May 10, 2016

This week, these five stocks have the best ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Great Earnings Growth — PDM CUBE TNP CSGS MAS

By Portfolio Grader May 3, 2016

This week, these five stocks have the best ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

Masco’s Rise on Housing Bullish For MAS Stock

By Zacks Investment Research Oct 30, 2015

Home building supplier Masco has seen its earnings improve as the housing industry rebounds. Masco is the Bull of the Day stock to buy

Hottest Capital Goods Stocks Now – NVR AWI DHI ST

By Portfolio Grader Oct 12, 2015

Capital goods stocks finished flat today on Wall Street.

Hottest Capital Goods Stocks Now – LPX TGI JHX MAS

By Portfolio Grader Oct 9, 2015

Capital goods stocks finished up 0.3% on Wall Street today.

Compare Brokers

Biggest Movers in Capital Goods Stocks Now – MLM TS DY CFX

By Portfolio Grader Oct 2, 2015

Capital goods stocks fell 1.4% on Wall Street so far on Friday.

Biggest Movers in Capital Goods Stocks Now – AMWD DY CX HW

By Portfolio Grader Sep 30, 2015

Capital goods stocks finished up 1.5% on Wall Street on Wednesday.

Lifestyle Drugs Market 2020 Analysis and Precise Outlook – Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience

From X herald Sep 19, 2020

Continue reading "Lifestyle Drugs Market 2020 Analysis and Precise Outlook – Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience"

Moderna and Pfizer set different efficacy bars in pivotal COVID-19 trials (NASDAQ:MRNA)

From Seeking Alpha Sep 19, 2020

Amid concerns among Americans that the rush to approve COVID-19 vaccines may lead to corner-cutting and end products that are not up to typical FDA efficacy standards, leading developers Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) have taken the unusual steps of publishing the protocols of the large-scale late-stage trials for their respective candidates.Moderna's Phase 3 trial of mRNA-1273, two 100 microgram doses 28 days apart, will recruit ~30K adults, 60-75% younger than 65 years old not at risk for complications and 25-40% at least 65 years old (the single most significant risk factor) or less than 65 at increased risk of COVID-19 complications.The primary efficacy endpoint is the incidence of first-occurrence COVID-19 cases starting 14 days after the second shot.A confirmed (via molecular test) COVID-19 case is defined as a participant who has experienced at least TWO of the following symptoms: fever (≥ 38ºC), chills, myalgia (muscle soreness), headache, sore throat, new olfactory and taste disorder(s) OR he/she must have experienced at least ONE of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing OR clinical or radiographic evidence of pneumonia.Pfizer and BioNTech's (NASDAQ:BNTX) Phase 3 study of BNT162b2, two 30 microgram doses 21 days apart, will recruit 30K adults stratified in two groups: 16-55 years old and 55+.The primary efficacy endpoint is the incidence of confirmed COVID-19 cases starting 7 days after the second shot as measured by the number of cases per 1,000 person-years of follow-up.A confirmed (via molecular test) COVID-19 case is defined as participants experiencing at least ONE of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased myalgia (muscle soreness), new loss of taste or smell, sore throat, diarrhea or vomiting.Moderna's criteria are a more restrictive and could potentially show a higher efficacy rate for mRNA-1273 as a result.The number of COVID-19 cases in people who just reported one symptom is unknown.

Business Chiefs Push Cuomo, de Blasio to Bolster NYC After Covid

From Bloomberg Sep 18, 2020

New York business leaders are pushing Governor Andrew Cuomo and Mayor Bill de Blasio to consider ways of ensuring that the nation’s biggest city retains its economic dominance in the wake of the coronavirus pandemic.

Epilepsy Drugs Market to See Huge Growth by 2026 : UCB Pharma, Pfizer, GlaxoSmithKline

From SBWire Sep 18, 2020

Stay up-to-date with Epilepsy Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.

Acute Coronary Syndrome Therapeutic Market Research Report by Type, by Drug, by Treatment, by Diagnosis, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

From BusinessInsider Sep 18, 2020

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Acute Coronary Syndrome Therapeutic Market Re...

Unusual Options Activity Insight: Pfizer

From Benzinga Sep 18, 2020

On Friday, shares of Pfizer (NYSE: PFE) saw unusual options activity. After the option alert, the stock price moved down to $36.69. Sentiment: BULLISH Option Type: SWEEP Trade...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy